Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivo
A Shieh, AF Ward, KL Donlan… - Blood, The Journal …, 2013 - ashpublications.org
Reversing the aberrant biochemical output of oncogenic Ras proteins is one of the great
challenges in cancer therapeutics; however, it is uncertain which Ras effectors are required …
challenges in cancer therapeutics; however, it is uncertain which Ras effectors are required …
Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivo
A Shieh, AF Ward, KL Donlan… - …, 2013 - pubmed.ncbi.nlm.nih.gov
Reversing the aberrant biochemical output of oncogenic Ras proteins is one of the great
challenges in cancer therapeutics; however, it is uncertain which Ras effectors are required …
challenges in cancer therapeutics; however, it is uncertain which Ras effectors are required …
[PDF][PDF] Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivo
A Shieh, AF Ward, KL Donlan, ER Harding-Theobald… - 2013 - researchgate.net
Somatic RAS mutations encode oncogenic proteins that accumulate in an active signaling
conformation. 1-3 Although the biophysical properties of Ras oncoproteins render them …
conformation. 1-3 Although the biophysical properties of Ras oncoproteins render them …
Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivo
A Shieh, AF Ward, KL Donlan… - …, 2013 - mdanderson.elsevierpure.com
Reversing the aberrant biochemical output of oncogenic Ras proteins is one of the great
challenges in cancer therapeutics; however, it is uncertain which Ras effectors are required …
challenges in cancer therapeutics; however, it is uncertain which Ras effectors are required …
[HTML][HTML] Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivo
A Shieh, AF Ward, KL Donlan, ER Harding-Theobald… - Blood, 2013 - Elsevier
Reversing the aberrant biochemical output of oncogenic Ras proteins is one of the great
challenges in cancer therapeutics; however, it is uncertain which Ras effectors are required …
challenges in cancer therapeutics; however, it is uncertain which Ras effectors are required …
[HTML][HTML] Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivo
A Shieh, AF Ward, KL Donlan, ER Harding-Theobald… - Blood, 2013 - ncbi.nlm.nih.gov
Reversing the aberrant biochemical output of oncogenic Ras proteins is one of the great
challenges in cancer therapeutics; however, it is uncertain which Ras effectors are required …
challenges in cancer therapeutics; however, it is uncertain which Ras effectors are required …
Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivo.
A Shieh, AF Ward, KL Donlan, ER Harding-Theobald… - Blood, 2013 - europepmc.org
Reversing the aberrant biochemical output of oncogenic Ras proteins is one of the great
challenges in cancer therapeutics; however, it is uncertain which Ras effectors are required …
challenges in cancer therapeutics; however, it is uncertain which Ras effectors are required …
Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivo.
A Shieh, AF Ward, KL Donlan, ER Harding-Theobald… - Blood, 2013 - europepmc.org
Reversing the aberrant biochemical output of oncogenic Ras proteins is one of the great
challenges in cancer therapeutics; however, it is uncertain which Ras effectors are required …
challenges in cancer therapeutics; however, it is uncertain which Ras effectors are required …